Diabetes, Vol 44, Issue 1 60-66, Copyright © 1995 by American Diabetes Association

ARTICLES

Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM

G Bellomo, E Maggi, M Poli, FG Agosta, P Bollati and G Finardi
Department of Medical Sciences, 2nd Faculty of Medicine, University of Torino, Novara, Italy.

Diabetes is an independent risk factor in the development of atherosclerosis, although the pathophysiological processes underlying this association are poorly understood. The oxidation of low-density lipoprotein (LDL) is considered a key event in the development and progression of atherosclerosis because it generates molecular epitopes that are more atherogenic than parent LDL. A total of 138 patients suffering from non-insulin-dependent diabetes mellitus (NIDDM) and 80 matched control subjects were investigated. LDL oxidation was evaluated as the presence of autoantibodies against oxidatively modified LDL, since they mirror the in vivo occurrence of oxidative processes. NIDDM patients had an antibody ratio (calculated as the ratio of antibodies against modified versus native LDL) significantly higher than control subjects for Cu(2+)-oxidized LDL (1.88 +/- 0.6 vs. 1.05 +/- 0.3, P < 0.01, for IgG), malondialdehyde-modified LDL (2.54 +/- 0.73 vs. 2.04 +/- 0.11, P < 0.01, for IgG and 3.96 +/- 1.51 vs. 2.90 +/- 0.15, P < 0.01, for IgM), and malondialdehyde-modified human serum albumin (1.79 +/- 0.54 vs. 1.46 +/- 0.1, P < 0.05 for IgG). The possible role played by glycation in sensitizing LDL to oxidation was investigated by measuring autoantibodies against both glycated LDL (glycLDL) and glycoxydated LDL (glycoxLDL). NIDDM patients had an antibody ratio significantly higher than control subjects for anti-glycLDL and anti-glycoxLDL IgG (1.79 +/- 0.38 vs. 1.12 +/- 0.23, P < 0.01 and 2.55 +/- 1.03 vs. 1.39 +/- 0.44, P < 0.01, respectively) but not anti-glycLDL and anti-glycox-LDL IgM.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E Albano, E Mottaran, M Vidali, E Reale, S Saksena, G Occhino, A D Burt, and C P Day Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis Gut, July 1, 2005; 54(7): 987 - 993. [Abstract] [Full Text] [PDF]

				F. Piarulli, A. Lapolla, G. Sartore, C. Rossetti, G. Bax, M. Noale, N. Minicuci, C. Fiore, L. Marchioro, E. Manzato, et al. Autoantibodies Against Oxidized LDLs and Atherosclerosis in Type 2 Diabetes Diabetes Care, March 1, 2005; 28(3): 653 - 657. [Abstract] [Full Text] [PDF]

				Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective? Circulation, October 26, 2004; 110(17): 2552 - 2558. [Full Text] [PDF]

				M. Schneider, B. Verges, A. Klein, E. R. Miller, V. Deckert, C. Desrumaux, D. Masson, P. Gambert, J.-M. Brun, J. Fruchart-Najib, et al. Alterations in Plasma Vitamin E Distribution in Type 2 Diabetic Patients With Elevated Plasma Phospholipid Transfer Protein Activity Diabetes, October 1, 2004; 53(10): 2633 - 2639. [Abstract] [Full Text] [PDF]

				S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, T. Iwasaka, and S. Fukuhara Activated Platelet and Oxidized LDL Induce Endothelial Membrane Vesiculation: Clinical Significance of Endothelial Cell-Derived Microparticles in Patients With Type 2 Diabetes Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 205 - 215. [Abstract] [PDF]

				G. Virella and M. F. Lopes-Virella Lipoprotein Autoantibodies: Measurement and Significance Clin. Vaccine Immunol., July 1, 2003; 10(4): 499 - 505. [Full Text] [PDF]

				R. H. Eckel, M. Wassef, A. Chait, B. Sobel, E. Barrett, G. King, M. Lopes-Virella, J. Reusch, N. Ruderman, G. Steiner, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of Atherosclerosis in Diabetes Circulation, May 7, 2002; 105 (18): e138 - e143. [Full Text] [PDF]

				H. A. Schenkein, C. R. Berry, D. Purkall, J. A. Burmeister, C. N. Brooks, and J. G. Tew Phosphorylcholine-Dependent Cross-Reactivity between Dental Plaque Bacteria and Oxidized Low-Density Lipoproteins Infect. Immun., November 1, 2001; 69(11): 6612 - 6617. [Abstract] [Full Text] [PDF]

				K. K. Koh, M. H. Kang, D. K. Jin, S.-K. Lee, J. Y. Ahn, H. Y. Hwang, S. H. Yang, D. S. Kim, T. H. Ahn, and E. K. Shin Vascular effects of estrogen in type II diabetic postmenopausal women J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1409 - 1415. [Abstract] [Full Text] [PDF]

				S. Devaraj, S. V. Hirany, R. F. Burk, and I. Jialal Divergence between LDL Oxidative Susceptibility and Urinary F2-Isoprostanes as Measures of Oxidative Stress in Type 2 Diabetes Clin. Chem., November 1, 2001; 47(11): 1974 - 1979. [Abstract] [Full Text] [PDF]

				J. D O'Reilly, A. I Mallet, G. T McAnlis, I. S Young, B. Halliwell, T. A. Sanders, and H. Wiseman Consumption of flavonoids in onions and black tea: lack of effect on F2-isoprostanes and autoantibodies to oxidized LDL in healthy humans Am. J. Clinical Nutrition, June 1, 2001; 73(6): 1040 - 1044. [Abstract] [Full Text] [PDF]

				G Hayem, P Nicaise-Roland, E Palazzo, M de Bandt, F Tubach, M Weber, and O Meyer Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome Lupus, May 1, 2001; 10(5): 346 - 351. [Abstract] [PDF]

				A. L. Herrick, K. J. Illingworth, S. Hollis, J. M. Gomez-Zumaquero, and F. J. Tinahones Antibodies against oxidized low-density lipoproteins in systemic sclerosis Rheumatology, April 1, 2001; 40(4): 401 - 405. [Abstract] [Full Text] [PDF]

				H. Deguchi, J. A. Fernandez, T. M. Hackeng, C. L. Banka, and J. H. Griffin Cardiolipin is a normal component of human plasma lipoproteins PNAS, February 15, 2000; 97(4): 1743 - 1748. [Abstract] [Full Text] [PDF]

				E. Ahmed, J. Trifunovic, B. Stegmayr, G. Hallmans, and A. K. Lefvert Autoantibodies Against Oxidatively Modified LDL Do Not Constitute a Risk Factor for Stroke : A Nested Case-Control Study Stroke, December 1, 1999; 30(12): 2541 - 2546. [Abstract] [Full Text] [PDF]

				K. C. B. Tan, V. H. G. Ai, W. S. Chow, M. T. Chau, L. Leong, and K. S. L. Lam Influence of Low Density Lipoprotein (LDL) Subfraction Profile and LDL Oxidation on Endothelium-Dependent and Independent Vasodilation in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3212 - 3216. [Abstract] [Full Text]

				M. S. Gowri, D. R. Van der Westhuyzen, S. R. Bridges, and J. W. Anderson Decreased Protection by HDL From Poorly Controlled Type 2 Diabetic Subjects Against LDL Oxidation May Be Due to the Abnormal Composition of HDL Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2226 - 2233. [Abstract] [Full Text] [PDF]

				T. QUASCHNING, M. SCHÖMIG, M. KELLER, J. THIERY, M. NAUCK, P. SCHOLLMEYER, C. WANNER, and A. KRÄMER-GUTH Non-Insulin-Dependent Diabetes Mellitus and Hypertriglyceridemia Impair Lipoprotein Metabolism in Chronic Hemodialysis Patients J. Am. Soc. Nephrol., February 1, 1999; 10(2): 332 - 341. [Abstract] [Full Text]

				S. Freigang, S. Horkko, E. Miller, J. L. Witztum, and W. Palinski Immunization of LDL Receptor–Deficient Mice With Homologous Malondialdehyde-Modified and Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neoepitopes Arterioscler. Thromb. Vasc. Biol., December 1, 1998; 18(12): 1972 - 1982. [Abstract] [Full Text] [PDF]

				P. Reaven, S. Merat, F. Casanada, M. Sutphin, and W. Palinski Effect of Streptozotocin-Induced Hyperglycemia on Lipid Profiles, Formation of Advanced Glycation Endproducts in Lesions, and Extent of Atherosclerosis in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2250 - 2256. [Abstract] [Full Text]

				A. D. Watson, N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, et al. Structural Identification by Mass Spectrometry of Oxidized Phospholipids in Minimally Oxidized Low Density Lipoprotein That Induce Monocyte/Endothelial Interactions and Evidence for Their Presence in Vivo J. Biol. Chem., May 23, 1997; 272(21): 13597 - 13607. [Abstract] [Full Text] [PDF]

				M. Seccia, E. Albano, E. Maggi, and G. Bellomo Circulating Autoantibodies Recognizing Peroxidase-Oxidized Low Density Lipoprotein: Evidence for New Antigenic Epitopes Formed In Vivo Independently From Lipid Peroxidation Arterioscler. Thromb. Vasc. Biol., January 1, 1997; 17(1): 134 - 140. [Abstract] [Full Text]

				M. I.J. Uusitupa, L. Niskanen, J. Luoma, P. Vilja, M. Mercuri, R. Rauramaa, and S. Yla-Herttuala Autoantibodies Against Oxidized LDL Do Not Predict Atherosclerotic Vascular Disease in Non–Insulin-Dependent Diabetes Mellitus Arterioscler. Thromb. Vasc. Biol., October 1, 1996; 16(10): 1236 - 1242. [Abstract] [Full Text]

				B. J. Auerbach, C. L. Bisgaier, J. Wölle, and U. Saxena Oxidation of Low Density Lipoproteins Greatly Enhances Their Association with Lipoprotein Lipase Anchored to Endothelial Cell Matrix J. Biol. Chem., January 19, 1996; 271(3): 1329 - 1335. [Abstract] [Full Text] [PDF]

				W. Palinski, R. K. Tangirala, E. Miller, S. G. Young, and J. L. Witztum Increased Autoantibody Titers Against Epitopes of Oxidized LDL in LDL Receptor–Deficient Mice With Increased Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 1995; 15(10): 1569 - 1576. [Abstract] [Full Text]